Global Anti-Venom Market Growth 2023-2029

Global Anti-Venom Market Growth 2023-2029

Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
LPI (LP Information)' newest research report, the “Anti-Venom Industry Forecast” looks at past sales and reviews total world Anti-Venom sales in 2022, providing a comprehensive analysis by region and market sector of projected Anti-Venom sales for 2023 through 2029. With Anti-Venom sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-Venom industry.
This Insight Report provides a comprehensive analysis of the global Anti-Venom landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-Venom portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Anti-Venom market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-Venom and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-Venom.
The global Anti-Venom market size is projected to grow from US$ 938.3 million in 2022 to US$ 1264.8 million in 2029; it is expected to grow at a CAGR of 1264.8 from 2023 to 2029.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Venom market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Polyvalent Anti-Venom
Monovalent Anti-Venom
Segmentation by application
Non-profit Institutions
Hospitals and Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm

Key Questions Addressed in this Report
What is the 10-year outlook for the global Anti-Venom market?
What factors are driving Anti-Venom market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-Venom market opportunities vary by end market size?
How does Anti-Venom break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.